PF 07328948
Alternative Names: PF-07328948Latest Information Update: 31 Jul 2024
At a glance
- Originator Pfizer
- Class Heart failure therapies
- Mechanism of Action Ketone oxidoreductase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Heart failure
Most Recent Events
- 10 Jul 2024 Pfizer completes a phase I trial in Heart failure (In volunteers) in USA and Belgium (PO, Tablet, Suspension) (NCT05807490)
- 05 Apr 2023 Phase-I clinical trials in Heart failure (In volunteers) in Belgium (PO) (NCT05807490)
- 05 Apr 2023 Pfizer initiates a phase I trial for Heart failure (In volunteers) in USA (PO, Suspension) (NCT05807490)